Degludec fares better than glargine in glucose control

04/23/2012 | Medical News Today

Type 2 diabetes patients who took insulin degludec showed lower rates of overall hypoglycemic episodes per year than their counterparts who received insulin glargine, according to two Phase III studies in The Lancet. Researchers also found that patients with type 1 or type 2 diabetes who were on degludec treatment had a 25% reduction in nocturnal hypoglycemia rates compared with those who took glargine.

View Full Article in:

Medical News Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX